{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:40:34Z","timestamp":1791272434602,"version":"4.1.0"},"reference-count":40,"publisher":"National Academy of Sciences","issue":"46","license":[{"start":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T00:00:00Z","timestamp":1493510400000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/www.pnas.org\/site\/misc\/userlicense.xhtml"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01 CA187299"],"award-info":[{"award-number":["1R01 CA187299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2016,11,15]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Autocrine cytokine signaling in cancer can activate members of the Janus kinase (JAK) family, which are generally thought to act by phosphorylating STAT family transcription factors. We report here that JAK1 mediates autocrine IL-6 and IL-10 cytokine signaling in activated B-cell\u2013like (ABC) diffuse large B-cell lymphoma (DLBCL) by a noncanonical epigenetic regulatory mechanism involving phosphorylation of histone H3 on tyrosine 41. We have identified target genes that are activated in ABC DLBCL by this epigenetic mechanism. Knowledge of these epigenetic targets led to our demonstration that JAK1 inhibitors synergize with inhibitors of active B cell receptor signaling in ABC DLBCL, suggesting a new therapeutic strategy for this subtype of DLBCL, which is the most difficult to cure with current therapy.<\/jats:p>","DOI":"10.1073\/pnas.1610970113","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T21:59:38Z","timestamp":1477951178000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":68,"title":["Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma"],"prefix":"10.1073","volume":"113","author":[{"given":"Lixin","family":"Rui","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"},{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Drennan","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Wright","sequence":"additional","affiliation":[{"name":"Biometric Research Branch, DCTD, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Xiao","sequence":"additional","affiliation":[{"name":"Division of Bioinformatics and Biostatistics, National Center for Toxicological Research\/Food and Drug Administration, Jefferson, AR 72079"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangguang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreg M.","family":"Grindle","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"},{"name":"Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Xu","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandan","family":"Yang","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh AA","year":"2000","unstructured":"AA Alizadeh, , Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz G","year":"2010","unstructured":"G Lenz, LM Staudt, Aggressive lymphomas. N Engl J Med 362, 1417\u20131429 (2010).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz G","year":"2008","unstructured":"G Lenz, , Stromal gene signatures in large-B-cell lymphomas. N Engl J Med; Lymphoma\/Leukemia Molecular Profiling Project 359, 2313\u20132323 (2008).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam LT","year":"2008","unstructured":"LT Lam, , Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111, 3701\u20133713 (2008).","journal-title":"Blood"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding BB","year":"2008","unstructured":"BB Ding, , Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515\u20131523 (2008).","journal-title":"Blood"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/0008-5472.CAN-10-2380","article-title":"STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma","volume":"71","author":"Scuto A","year":"2011","unstructured":"A Scuto, , STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 71, 3182\u20133188 (2011).","journal-title":"Cancer Res"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"a000109","DOI":"10.1101\/cshperspect.a000109","article-title":"Oncogenic activation of NF-kappaB","volume":"2","author":"Staudt LM","year":"2010","unstructured":"LM Staudt, Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2, a000109 (2010).","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis RE","year":"2001","unstructured":"RE Davis, KD Brown, U Siebenlist, LM Staudt, Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194, 1861\u20131874 (2001).","journal-title":"J Exp Med"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo VN","year":"2011","unstructured":"VN Ngo, , Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115\u2013119 (2011).","journal-title":"Nature"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang Y","year":"2012","unstructured":"Y Yang, , Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723\u2013737 (2012).","journal-title":"Cancer Cell"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis RE","year":"2010","unstructured":"RE Davis, , Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88\u201392 (2010).","journal-title":"Nature"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno M","year":"2009","unstructured":"M Compagno, , Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717\u2013721 (2009).","journal-title":"Nature"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz G","year":"2008","unstructured":"G Lenz, , Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676\u20131679 (2008).","journal-title":"Science"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson WH","year":"2015","unstructured":"WH Wilson, , Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21, 922\u2013926 (2015).","journal-title":"Nat Med"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark GR","year":"2012","unstructured":"GR Stark, Jr JE Darnell, The JAK-STAT pathway at twenty. Immunity 36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2012.03.017","article-title":"Janus kinase deregulation in leukemia and lymphoma","volume":"36","author":"Chen E","year":"2012","unstructured":"E Chen, LM Staudt, AR Green, Janus kinase deregulation in leukemia and lymphoma. Immunity 36, 529\u2013541 (2012).","journal-title":"Immunity"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea JJ","year":"2013","unstructured":"JJ O\u2019Shea, SM Holland, LM Staudt, JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368, 161\u2013170 (2013).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1534\/g3.113.007674","article-title":"STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma","volume":"3","author":"Hardee J","year":"2013","unstructured":"J Hardee, , STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma. G3 (Bethesda) 3, 2173\u20132185 (2013).","journal-title":"G3 (Bethesda)"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ng1860","article-title":"JAK signaling globally counteracts heterochromatic gene silencing","volume":"38","author":"Shi S","year":"2006","unstructured":"S Shi, , JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 38, 1071\u20131076 (2006).","journal-title":"Nat Genet"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson MA","year":"2009","unstructured":"MA Dawson, , JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819\u2013822 (2009).","journal-title":"Nature"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui L","year":"2010","unstructured":"L Rui, , Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18, 590\u2013605 (2010).","journal-title":"Cancer Cell"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ncb2135","article-title":"LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease","volume":"13","author":"Griffiths DS","year":"2011","unstructured":"DS Griffiths, , LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 13, 13\u201321 (2011).","journal-title":"Nat Cell Biol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson MA","year":"2012","unstructured":"MA Dawson, T Kouzarides, Cancer epigenetics: From mechanism to therapy. Cell 150, 12\u201327 (2012).","journal-title":"Cell"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ni.2094","article-title":"Malignant pirates of the immune system","volume":"12","author":"Rui L","year":"2011","unstructured":"L Rui, R Schmitz, M Ceribelli, LM Staudt, Malignant pirates of the immune system. Nat Immunol 12, 933\u2013940 (2011).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl C","year":"2011","unstructured":"C Steidl, , MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377\u2013381 (2011).","journal-title":"Nature"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat M","year":"2009","unstructured":"M Hedvat, , The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487\u2013497 (2009).","journal-title":"Cancer Cell"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa RA","year":"2012","unstructured":"RA Mesa, U Yasothan, P Kirkpatrick, Ruxolitinib. Nat Rev Drug Discov 11, 103\u2013104 (2012).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg JF","year":"1999","unstructured":"JF Bromberg, , Stat3 as an oncogene. Cell 98, 295\u2013303 (1999).","journal-title":"Cell"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1073\/pnas.98.4.1543","article-title":"Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1","volume":"98","author":"Shen Y","year":"2001","unstructured":"Y Shen, G Devgan, Jr JE Darnell, JF Bromberg, Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 98, 1543\u20131548 (2001).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer AL","year":"2006","unstructured":"AL Shaffer, , A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210, 67\u201385 (2006).","journal-title":"Immunol Rev"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood-2015-07-655647","article-title":"CARMA1- and MyD88-dependent activation of Jun\/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas","volume":"127","author":"Juilland M","year":"2016","unstructured":"M Juilland, , CARMA1- and MyD88-dependent activation of Jun\/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood 127, 1780\u20131789 (2016).","journal-title":"Blood"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/35001102","article-title":"How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis","volume":"403","author":"Glynne R","year":"2000","unstructured":"R Glynne, , How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis. Nature 403, 672\u2013676 (2000).","journal-title":"Nature"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1084\/jem.188.12.2215","article-title":"The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells","volume":"188","author":"Dinkel A","year":"1998","unstructured":"A Dinkel, , The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells. J Exp Med 188, 2215\u20132224 (1998).","journal-title":"J Exp Med"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-13-0466","article-title":"Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma","volume":"13","author":"Qin Z","year":"2014","unstructured":"Z Qin, , Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 13, 154\u2013164 (2014).","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/gb-2014-15-1-r12","article-title":"Global target mRNA specification and regulation by the RNA-binding protein ZFP36","volume":"15","author":"Mukherjee N","year":"2014","unstructured":"N Mukherjee, , Global target mRNA specification and regulation by the RNA-binding protein ZFP36. Genome Biol 15, R12 (2014).","journal-title":"Genome Biol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1242\/jcs.113.16.2813","article-title":"SOCS: Physiological suppressors of cytokine signaling","volume":"113","author":"Krebs DL","year":"2000","unstructured":"DL Krebs, DJ Hilton, SOCS: Physiological suppressors of cytokine signaling. J Cell Sci 113, 2813\u20132819 (2000).","journal-title":"J Cell Sci"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ncb1713","article-title":"Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability","volume":"10","author":"Shi S","year":"2008","unstructured":"S Shi, , Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat Cell Biol 10, 489\u2013496 (2008).","journal-title":"Nat Cell Biol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1101\/gad.1553707","article-title":"Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB","volume":"21","author":"Yang J","year":"2007","unstructured":"J Yang, , Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21, 1396\u20131408 (2007).","journal-title":"Genes Dev"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz DM","year":"2016","unstructured":"DM Schwartz, M Bonelli, M Gadina, JJ O\u2019Shea, Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12, 25\u201336 (2016).","journal-title":"Nat Rev Rheumatol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo VN","year":"2006","unstructured":"VN Ngo, , A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106\u2013110 (2006).","journal-title":"Nature"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1610970113","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1610970113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:08:24Z","timestamp":1654600104000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1610970113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":40,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2016,11,15]]}},"alternative-id":["10.1073\/pnas.1610970113"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1610970113","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]},"assertion":[{"value":"2016-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}